Erik Ryberg

2.4k total citations · 1 hit paper
15 papers, 1.9k citations indexed

About

Erik Ryberg is a scholar working on Pharmacology, Cellular and Molecular Neuroscience and Surgery. According to data from OpenAlex, Erik Ryberg has authored 15 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pharmacology, 7 papers in Cellular and Molecular Neuroscience and 6 papers in Surgery. Recurrent topics in Erik Ryberg's work include Cannabis and Cannabinoid Research (8 papers), Pancreatic function and diabetes (5 papers) and Neuroscience and Neuropharmacology Research (4 papers). Erik Ryberg is often cited by papers focused on Cannabis and Cannabinoid Research (8 papers), Pancreatic function and diabetes (5 papers) and Neuroscience and Neuropharmacology Research (4 papers). Erik Ryberg collaborates with scholars based in Sweden, United Kingdom and United States. Erik Ryberg's co-authors include Peter J. Greasley, Stephan Hjorth, Thomas Elebring, Niklas Larsson, Nils-Olov Hermansson, Peter Nilsson, Tomáš Drmota, S. Sjögren, Ken Mackie and Lauren S. Whyte and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Biochemical Journal.

In The Last Decade

Erik Ryberg

14 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The orphan receptor GPR55 is a novel cannabinoid receptor

2007 1.2k citations Erik Ryberg, Niklas Larsson et al. British Journal of Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erik Ryberg Sweden	12	1.5k	725	422	366	308	15	1.9k
Nils-Olov Hermansson Sweden	7	1.1k 0.7×	543 0.7×	282 0.7×	234 0.6×	214 0.7×	8	1.4k
Jean Marchand France	7	1.9k 1.3×	935 1.3×	307 0.7×	292 0.8×	224 0.7×	15	2.1k
Jeanne Maruani France	7	2.1k 1.4×	1.5k 2.1×	264 0.6×	176 0.5×	165 0.5×	8	2.4k
Sravan K. Goparaju Japan	21	1.8k 1.2×	671 0.9×	1.1k 2.7×	478 1.3×	566 1.8×	24	3.4k
Somnath Mukhopadhyay United States	21	904 0.6×	637 0.9×	373 0.9×	179 0.5×	77 0.3×	31	1.3k
John C. Ashton New Zealand	18	963 0.6×	614 0.8×	308 0.7×	125 0.3×	71 0.2×	67	1.5k
Xavier Canat France	11	969 0.7×	919 1.3×	486 1.2×	218 0.6×	79 0.3×	12	1.6k
Yuki Yamasaki Japan	13	641 0.4×	463 0.6×	250 0.6×	139 0.4×	126 0.4×	50	1.3k
Haleli Sharir United States	14	641 0.4×	419 0.6×	514 1.2×	213 0.6×	156 0.5×	17	1.2k
Angelo Vaccani Italy	11	860 0.6×	404 0.6×	299 0.7×	173 0.5×	118 0.4×	15	1.2k

Countries citing papers authored by Erik Ryberg

Since Specialization

Citations

This map shows the geographic impact of Erik Ryberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Ryberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Ryberg more than expected).

Fields of papers citing papers by Erik Ryberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Ryberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Ryberg. The network helps show where Erik Ryberg may publish in the future.

Co-authorship network of co-authors of Erik Ryberg

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Ryberg. A scholar is included among the top collaborators of Erik Ryberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Ryberg. Erik Ryberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Wainwright, Cherry L., et al.. (2025). Short‐Term Oral Administration of the Porcupine Inhibitor, Wnt‐c59, Improves the Structural and Functional Features of Experimental HFpEF. Pharmacology Research & Perspectives. 13(1). e70054–e70054. 2 indexed citations

Birnbaum, Yochai, Huan Chen, Leif Carlsson, et al.. (2022). Recombinant Apyrase (AZD3366) Against Myocardial Reperfusion Injury. Cardiovascular Drugs and Therapy. 37(4). 625–646. 6 indexed citations

Tyrberg, Björn, Charlotte Wennberg Huldt, Peter Gennemark, et al.. (2020). Inhibition of the prostaglandin D2–GPR44/DP2 axis improves human islet survival and function. Diabetologia. 63(7). 1355–1367. 13 indexed citations

Walsh, Sarah K., et al.. (2019). l‐α‐Lysophosphatidylinositol (LPI) aggravates myocardial ischemia/reperfusion injury via a GPR55/ROCK‐dependent pathway. Pharmacology Research & Perspectives. 7(3). e00487–e00487. 34 indexed citations

Lundin, Anders, David Gustafsson, J. Fryklund, et al.. (2018). Plasminogen binding inhibitors demonstrate unwanted activities on GABA A and glycine receptors in human iPSC derived neurons. Neuroscience Letters. 681. 37–43.

Skrtic, Stanko, Björn Tyrberg, Hans Ericsson, et al.. (2018). Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients. PLoS ONE. 13(12). e0208998–e0208998. 11 indexed citations

Bjursell, Mikael, Erik Ryberg, Tingting Wu, et al.. (2016). Deletion of Gpr55 Results in Subtle Effects on Energy Metabolism, Motor Activity and Thermal Pain Sensation. PLoS ONE. 11(12). e0167965–e0167965. 27 indexed citations

Rosengren, Birgitta, et al.. (2015). AZD8797 is an allosteric non-competitive modulator of the human CX3CR1 receptor. Biochemical Journal. 473(5). 641–649. 42 indexed citations

Walsh, Sarah K., Annika Åstrand, Anna Lindblom, et al.. (2015). Pharmacological profiling of the hemodynamic effects of cannabinoid ligands: a combined in vitro and in vivo approach. Pharmacology Research & Perspectives. 3(3). e00143–e00143. 21 indexed citations

10.

Sundström, Linda, et al.. (2013). Succinate receptor GPR91, a Gα _i coupled receptor that increases intracellular calcium concentrations through PLCβ. FEBS Letters. 587(15). 2399–2404. 45 indexed citations

11.

Trembovler, Victoria, Alexander Alexandrovich, Erik Ryberg, et al.. (2011). N-Arachidonoyl-l-Serine is Neuroprotective after Traumatic Brain Injury by Reducing Apoptosis. Journal of Cerebral Blood Flow & Metabolism. 31(8). 1768–1777. 48 indexed citations

12.

Boström, Jonas, et al.. (2009). Novel thioamide derivatives as neutral CB1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 20(2). 479–482. 24 indexed citations

13.

Whyte, Lauren S., Erik Ryberg, Natalie A. Sims, et al.. (2009). The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proceedings of the National Academy of Sciences. 106(38). 16511–16516. 258 indexed citations

14.

Ryberg, Erik, Niklas Larsson, S. Sjögren, et al.. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology. 152(7). 1092–1101. 1249 indexed citations breakdown →

15.

Ryberg, Erik, Huy Khang Vu, Niklas Larsson, et al.. (2004). Identification and characterisation of a novel splice variant of the human CB1 receptor. FEBS Letters. 579(1). 259–264. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact